This article summarizes recent research on the ontogeny of Langerhans cells and regulation of their homeostasis in quiescent and inflamed conditions.
INTRODUCTION
Langerhans cells are myeloid cells resident in the epidermis and stratified epithelia of the corneal, buccal, gingival and genital mucosae [1] . They were first described by Paul Langerhans as neurons [2] , but the advent of monoclonal antibodies revealed the expression of major histocompatibility complex class II and macrophage antigens [3, 4] and a potential bone marrow origin [5] . Langerhans cells soon became the paradigm of migratory dendritic cells; tissue-resident sentinels that could capture antigen, migrate to lymph nodes and develop potent immunostimulatory capacity [6, 7] . In recent years, however, the story of Langerhans cells has become more complex. Langerhans cells, microglia and many populations of tissue macrophages have their earliest origins from primitive yolk sac hematopoiesis and may persist by local self-renewal for the entire life of an organism. These exciting developments have revised the concept of a mononuclear phagocyte system in which, previously, macrophages and other resident myeloid cells were thought to be continually replenished by monocytes [8] .
Langerhans cells have now become a new exemplar of the bone marrow-independent tissue-resident myeloid cell, or macrophage [9] , although uniquely, they retain genuine dendritic cell function. Critically, the demonstration of a primitive origin does not exclude a secondary origin from bone marrow and the Langerhans cell network is renewed by bone marrow-derived cells following severe inflammation [10, 11] . New work has revealed that this occurs in two waves, involving classical monocytes and an uncharacterized myeloid progenitor.
Recent studies have also examined the molecular regulation of Langerhans cell development. The requirement of Langerhans cells to integrate into an epithelial layer and then to disengage from this layer demands special properties that may be instructive to compare with mesenchymal to epithelial transitions [12] . A key conceptual advance has been to draw a distinction between mechanisms involved in the development of Langerhans cells and those required for the maintenance of a stable Langerhans cell network.
THE PRENATAL ORIGIN OF LANGERHANS CELLS
Mammalian hematopoiesis has multiple overlapping origins. The first myeloid cells, so-called yolk sac macrophages, are generated from primitive erythro-myeloid progenitors (EMP) in the yolk sac between days 7 and 9 of mouse embryogenesis and at about 16-18 days of human gestation. EMPs have restricted potential and do not produce definitive long-term multipotent hematopoietic stem cells (HSCs). The majority of definitive HSCs arise in the aorta-gonad-mesonephros region after day 9 in the mouse (day 32 in humans) and migrate first to the fetal liver and then to the bone marrow. Primitive waves of restricted hematopoiesis may contribute to fetal liver hematopoiesis overlapping with but independent of the adult HSC pool.
A PRIMITIVE ORIGIN OF LANGERHANS CELLS FROM YOLK SAC MACROPHAGES
It has been known for many years that yolk sac macrophages migrate throughout the embryonic tissues, entering the rudimentary skin and brain. However, fate-mapping experiments have only recently revealed that these primitive macrophages proliferate in situ giving rise to long-lived populations of Langerhans cells, microglia and macrophages that persist into postnatal and adult life (reviewed in [13] ). The development of Langerhans cells and microglia is also critically dependent upon the local production of interleukin-34 acting through the macrophage-colony stimulating factor receptor [14, 15] .
THE CONTRIBUTION OF FETAL LIVER MONOCYTES TO LANGERHANS CELL DEVELOPMENT
In the brain, microglia arise exclusively from yolk sac macrophages, as demonstrated by Ginhoux et al. [16] using a Runx1 inducible fate-mapping system. The same technique applied to Langerhans cells yielded a more complex result in which Langerhans cells were initially labeled to the same level as microglia when the marker was activated at day 7.5, but between days 13.5 and birth, the level of marker fell by at least twothirds. The authors interpreted this as evidence for a secondary origin of Langerhans cells from the unlabeled fetal liver, via a monocyte-like precursor potentially derived from definitive hematopoiesis [17] . However, this result was challenged by Geissmann and colleagues [18] who adopted a powerful genetic strategy to demonstrate that Langerhans cells could develop in the absence of c-myb and flt3, obligate factors for the formation of definitive HSCs. This led them to propose that Langerhans cells were mainly derived from EMPs via a yolk sac macrophage intermediate, although they could not completely exclude an additional contribution of definitive hematopoiesis to the Langerhans cell pool with these experiments. In a subsequent study, fate-mapping with CSF-1 and flt-3 inducible markers that tag primitive and definitive hematopoiesis, respectively, showed that primitive EMPs made substantial contributions to fetal liver myelopoiesis until day 16.5 [19 & ]. This important finding suggested that the fetal liver monocyte proposed by Ginhoux to be a significant precursor of the Langerhans cell pool was ultimately derived from primitive hematopoiesis ( Fig. 1 ).
A DISTINCT POPULATION OF YOLK SAC PROGENITORS GIVES RISE TO LANGERHANS CELLS VIA FETAL LIVER MONOCYTES
A further study in which fetal liver monocytes were specifically tagged found evidence that they were indeed derived from primitive EMPs generated in
KEY POINTS
Langerhans cells arise from primitive EMPs generated in the yolk sac via two routes: c-myb-independent yolk sac macrophages and c-mybþ fetal liver monocytes.
Langerhans cells form a stable self-renewing network that does not require bone marrow-derived precursors in postnatal life, in the absence of inflammation.
Distinct TGFb signaling pathways are involved in the development of Langerhans cells and maintenance of their homeostasis.
Inflammation recruits two waves of Langerhans cell precursors: a transient population of classical monocytes followed by a second wave of uncharacterized myeloid cells that creates a new stable Langerhans cell network.
In-vitro experiments in humans suggest that myeloid dendritic cells have Langerhans cell potential but whether this lineage provides the stable Langerhans cell population after inflammation remains speculative.
the yolk sac, in broad agreement with the results of Geissmann and colleagues [20 && ]. However, crucially, Langerhans cells and tissue macrophages were found to originate from a distinct subset of late c-myb þ EMPs that did not form yolk sac macrophages but which gave rise to fetal liver monocytes. Broadly speaking, this result resolves the controversy by showing that Langerhans cells can arise from primitive EMPs via the fetal liver. However, there is still disagreement about the relative importance of two distinct routes: the c-myb-independent yolk sac macrophage described by Geissmann and colleagues and the c-myb þ fetal liver monocyte that takes over once the circulation is established. Both groups showed that a third component of flt-3-dependent definitive hematopoiesis makes a minor contribution ( Fig. 1 ). It has been postulated that resident cells laid down by primitive waves of myelopoiesis have intrinsic differences from those recruited from the progeny of definitive hematopoiesis in postnatal life [21] . Much more work is required to expound this concept; although some evidence is described in cardiac tissue macrophages [22] , studies are currently lacking in Langerhans cells.
BONE MARROW INDEPENDENCE OF HUMAN LANGERHANS CELLS
Human hematopoiesis also begins in yolk sac blood islands and transitions through the fetal liver to the bone marrow in a similar sequence but is fully established in the adult pattern by birth. Human Langerhans cells are fully formed at the practical limit of studies on human fetuses at around weeks 18-24 [23, 24] .
A number of lines of evidence corroborate the view that Langerhans cells are self-renewing and independent of bone marrow precursors in humans: Langerhans cells in skin grafts onto xenogeneic hosts incorporate BrdU and proliferate [25] ; human limb transplants maintain donor-type Langerhans cells [26] ; and humans with GATA2 or interferon response factor 8 (IRF8) mutation have persisting Langerhans cells and tissue macrophages, despite complete absence of circulating monocytes and dendritic cells [27, 28] . GATA2 is another factor that is required for definitive hematopoiesis, whereas IRF8 is required for the terminal differentiation of monocytes and dendritic cells. A systematic study of the role of IRF8, IRF4, PU.1 and Id2 in Langerhans cell development shows concordant results with human IRF8 mutation [29] .
Following human bone marrow transplantation, rapid replenishment of Langerhans cells by bone marrow-derived cells is reported, even after nonmyeloablative conditioning in the absence of overt graft versus host disease [30] [31] [32] , although one recent study does not concur with these results [33] . This contrasts with the finding in mice in which recipient Langerhans cells show robust survival after bone marrow transplantation [34] . Multiple factors may combine to limit the capacity of human Langerhans cells to self-renew following bone marrow transplantation: human recipients are many decades older than neonatal laboratory mice; human skin is continually exposed to ultraviolet light; and, patients have usually been treated with multiple cytoreductive drugs.
SELF-RENEWAL OF LANGERHANS CELLS IN THE ABSENCE OF INFLAMMATION
Approximately 2-5% of Langerhans cells express Ki-67 and are in cell cycle in the steady state. Staining of epidermal sheets reveals pairs of daughter cells scattered across the interfollicular regions [35, 36] . A beautiful random-color fate-mapping tool has been used to show that equal-sized patches of epidermis are colonized by the progeny of multiple individual Langerhans cells that enter the skin during development [37] . Attempts to define a subset of Langerhans cells that act as local 'stem cells' have been unsuccessful suggesting that the mature Langerhans cells have an intrinsic ability to enter cell cycle when required. The regulation of Langerhans cell densi ty is incompletely understood, but ablation of mTORC1 [38] or disruption of extracellular signalregulated kinase (ERK)/mechanistic target of rapamycin (mTOR) signaling via targeted ablation of the adaptor protein p14 leads to failure of Langerhans cell homeostasis soon after birth [39 & ]. The loss of p14 has recently been shown to interfere with transforming growth factor beta (TGFb) signaling [40] . Mice with these mutations are also unable to form long-term resident Langerhans cell populations after inflammation.
The importance of TGFb signaling in human and mouse Langerhans cell development has been known for many years [41] [42] [43] . The failure of Langerhans cell development in Runx3 and Id2 knockout mice is also linked to the observation that Runx3 is required for transcription of Id2, a key target gene of TGFb. A permissive role of Pu.1 in activating Runx3 expression has also recently been highlighted [29] .
Recent data recognize a distinction between TGFb signaling pathways that affect the initial formation of Langerhans cells and those required to promote stability of the Langerhans cell network (Fig. 2) . Surprisingly, although adult TGFb knockout mice lack Langerhans cells, deletion of the classical TGFb receptor chain TGFbRI/anaplastic lymphoma kinase (ALK)5 did not prevent the formation of Langerhans cells but caused early attrition of the network through enhanced migration of Langerhans cells in early postnatal life [44, 45] .
This conundrum has recently been addressed by the elegant work of Strobl and colleagues [46] showing that alternative TGFb signaling involving bone morphogenetic protein 7 (BMP7), the ALK3 receptor and phosphorylation of smad 1/5/8, is prominent in Langerhans cell development. In contrast, signals transduced through TGFbRI/ALK5 and smad2/3 appear to be more important in maintaining homeostasis of the Langerhans cell network. Numerous mechanisms are cited for this effect including the expression of adhesion molecules epithelial cell adhesion molecule (EpCAM), TROP2, E-Cadherin and b-catenin [47] . Another critical pathway maintaining Langerhans cell in a quiescent state in response to TGFb is the expression of Axl, a member of the Tyro Axl Mer family of receptors for apoptotic cells (Tyro3, Axl and Mer). Axl ligand Gas 6 is abundant in the suprabasal epidermis and Axl expression maintains toll-like receptor hyporesponsiveness, contributing to the stability of the Langerhans cell network [48] .
REPLENISHMENT OF LANGERHANS CELLS AFTER INFLAMMATORY INSULTS
Inflammation of the epidermis results in increased turnover and trafficking of Langerhans cells to draining lymph nodes [49] . In atopic conditions, proliferation increases to meet this demand [35] but denudation of the epidermis recruits de-novo bone marrow-derived progenitors. Several studies have demonstrated a two-wave reconstitution of the Langerhans cell compartment involving a transient population of classical monocytes followed by a myeloid precursor that restores stable self-renewing Langerhans cells (Fig. 3) . The initial wave of monocyte-derived Langerhans cells retains markers Gr-1 and lysozyme and develops low langerin and EpCAM expression [50] [51] [52] . A microscopic dissection of this process showed that CCL2 and CCL20 (CCR2 and CCR6 ligands, respectively) are expressed by discrete portions of the hair follicle that function as portals for monocyte recruitment [51] . Four to six weeks later, after inflammation has subsided, Id2dependent Langerhans cells with high langerin and EpCAM are observed, originating by an uncertain pathway from the bone marrow [52] . Previous studies in mice implicating flt-3-dependent pathways in the long-term reconstitution of Langerhans cells suggest that a second wave of precursors may be derived from classical dendritic cell progenitors [10, 53] . Further experiments in mice are warranted to test the potential of blood dendritic cells and predendritic cells to provide long-term Langerhans cell reconstitution in the absence of monocytes. The existence of a second wave of Langerhans cell precursors is not universally accepted and long-term survival of the Langerhans cell network (up to 6 weeks) was recently reported in a lineage-restricted Id2 knockout mouse model [29] . Strain and preparative differences may explain some of this discrepancy and further confirmation of the two-wave model is required.
TWO HUMAN LANGERHANS CELL PRECURSORS?
In humans, CD14 þ monocytes can be induced to express langerin in response to GM-CSF, interleukin-4 and TGFb [54, 55] . In addition, two recent articles highlight the potential of CD1c þ blood dendritic cells to acquire high levels of langerin and CD1a, forming Langerhans cell-like cells in vitro in response to thymic stromal lymphopoietin (TSLP) and TGFb [ ] although it is possible that this difference is effaced when monocytes are activated with Notch ligands as might occur in vivo [55, 58] . A unifying hypothesis that accounts for the expression of langerin by both monocytes and CD1c þ dendritic cells is that they represent the two waves of repopulation reported in mouse models. A number of previous observations are accommodated by this model. First, the puzzling report of CD1a þ 'Langerhans cell precursors' in human blood [59] is reconciled by the knowledge that the antibody clone used to detect CD1a in this study is actually specific for CD1c, thus correctly identifying the CD1c þ dendritic cell as a potential Langerhans cell precursor [60] . Second, the claim that CD14 þ dermal cells are Langerhans cell precursors [61] is consistent with recent studies showing that they are related to monocytes and therefore might be induced to express langerin at a low level [62] . Finally, the search for langerin þ dendritic cells in humans revealed small populations of langerin þ CD1c þ dendritic cells in the dermis, lung and lymph node [63] . These cells are distinct from and independent of Langerhans cells in the steady state, but the expression of langerin may reflect a latent potential of dendritic cell precursors to differentiate into Langerhans cells under inflammatory conditions. There are many differences between classical monocytes and CD1c þ dendritic cells at the molecular level and it will be very interesting to unravel the critical factors, possibly involving Runx3 and Id2, which might permit Langerhans cell differentiation from a dendritic cell lineage.
LANGERHANS CELL NEOPLASIA
Understanding the regulation of Langerhans cell development and homeostasis has important implications for a human disease, Langerhans cell histiocytosis (LCH). LCH has the hallmarks of a 'functional neoplasia', that is a fundamentally neoplastic disease that retains functions of a normal cellular counterpart. LCH is caused by activating mutations of the ras-activated factor/MAPK ERK kinase/ERK pathway that result in accumulation of Langerhans-like cells with an immature phenotype in ectopic sites [64] [65] [66] . The study of normal Langerhans cell development may identify survival signaling circuits that can be interrupted or differentiation pathways through which maturation and senescence may be induced, in order to treat this disease. The subtle dysregulation of ERK that causes LCH also illustrates how critically poised the development of Langerhans cells is in healthy conditions.
CONCLUSION
The study of Langerhans cells continues to provide conceptually challenging results. Langerhans cells are an exemplar of a resident myeloid cell population arising from primitive hematopoiesis and able to self-renew throughout life. Future studies will be aimed at uncovering functional differences between long-term resident myeloid cells and those recruited by an inflammatory insult. In ontogeny and after inflammation, Langerhans cell precursors come in waves. At first sight, there are many differences between the precursor populations involved in these two processes. However, further studies are required to understand exactly which aspects of the developmental program that generated Langerhans cells in prenatal life are recapitulated in the replenishment of a stable Langerhans cell network after inflammation. Langerhans cell development is complex and signals that control the development and differentiation of Langerhans cells are distinct from those that maintain a stable Langerhans cell network. More work is required to unravel these mechanisms. It seems likely that the Langerhans cell has yet more secrets to reveal that will have wide ranging impacts in the field of myeloid cell biology.
